A Genomic Strategy to Refine Prognosis in Early-Stage Non–Small-Cell Lung Cancer
Open Access
- 10 August 2006
- journal article
- retracted article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (6) , 570-580
- https://doi.org/10.1056/nejmoa060467
Abstract
Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA — but not stage IA — non–small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of an individual patient. Indeed, approximately 25 percent of patients with stage IA disease have a recurrence after surgery, suggesting the need to identify patients in this subgroup for more effective therapy.Keywords
This publication has 30 references indexed in Scilit:
- Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted TherapyJournal of Clinical Oncology, 2005
- Multidisciplinary Management of Lung CancerNew England Journal of Medicine, 2004
- Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung CancerNew England Journal of Medicine, 2004
- Prognostic Factors in Non-small Cell Lung CancerChest, 2002
- Lung cancerThe Lancet, 2000
- A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markersThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Revisions in the International System for Staging Lung CancerChest, 1997
- Survival in early-stage non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- The New International Staging System for Lung CancerSurgical Clinics of North America, 1987